Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer

References

• JungYDMansfieldPFAkagiMEffects of combination antivascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse modelEur J Cancer20023881133114012008203
   PubMed Web of Science ®Google Scholar
• KerbelRSTumor angiogenesisN Engl J Med2008358192039204918463380
   PubMed Web of Science ®Google Scholar
• GridelliCMaionePRossiADe MarinisFThe role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developmentsOncologist200712101183119317962612
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAILJ Clin Oncol20092781227123419188680
   PubMed Web of Science ®Google Scholar
• ArteagaCTargeting HER1/EGFR: a molecular approach to cancer therapySemin Oncol2003303 Suppl 7314
   Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• HerbstRSPragerDHermannRTRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol200523255892589916043829
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol201011652152920493771
   PubMed Web of Science ®Google Scholar
• O’ReillyMSTherapeutic strategies using inhibitors of angiogenesisMethods Mol Biol200322359963412777753
   PubMedGoogle Scholar
• HerbstRSJohnsonDHMininbergEPhase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerJ Clin Oncol200523112544255515753462
   PubMed Web of Science ®Google Scholar
• HerbstRSO’NeillVJFehrenbacherLPhase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancerJ Clin Oncol200725304743475017909199
   PubMed Web of Science ®Google Scholar
• HerbstRSAnsariRBustinFEfficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trialLancet201137797801846185421621716
   PubMed Web of Science ®Google Scholar
• MillwardMJBoyerMJLehnertMDocetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patientsAnn Oncol200314344945412598352
   PubMed Web of Science ®Google Scholar
• ZarogoulidisKKontakiotisTHatziapostolouPA Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancerLung Cancer200132328128711390009
   PubMed Web of Science ®Google Scholar
• CascinuSStaccioliMPGaspariniGExpression of vascular endothelial growth factor can predict event-free survival in stage II colon cancerClin Cancer Res2000672803280710914727
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• FaulFErdfelderELangAGBuchnerAG*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciencesBehav Res Methods200739217519117695343
   PubMed Web of Science ®Google Scholar
• NaumovGNNilssonMBCasconeTCombined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistanceClin Cancer Res200915103484349419447865
   PubMed Web of Science ®Google Scholar
• SattlerMAbidoyeOSalgiaREGFR-targeted therapeutics: focus on SCCHN and NSCLCScientific World Journal2008890991918836658
   PubMed Web of Science ®Google Scholar
• HannaNShepherdFAFossellaFVRandomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ Clin Oncol20042291589159715117980
   PubMed Web of Science ®Google Scholar
• MillerVAO’ConnorPSohCATLAS InvestigatorsA randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)J Clin Oncol.200927Suppl 18Abstr LBA8002
   Web of Science ®Google Scholar
• TimotheadouESkarlosDVSamantasEEvaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patientsAnticancer Res2007276C4481448918214064
   PubMed Web of Science ®Google Scholar
• PaoWMillerVZakowskiMEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to geftinib and erlotinibProc Natl Acad Sci USA200410136133061331115329413
   PubMed Web of Science ®Google Scholar
• ReguartNCardonaAFRosellRRole of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancerCancer Manag Res2010214315621188105
   PubMedGoogle Scholar